Johnson & Johnson has started a marketing application in the US for TAR-200 as a treatment for non-muscle-invasive bladder cancer (NMIBC). Artificial intelligence (AI) has long promised to ...

BofA analyst Tim Anderson lowered the firm’s price target on Johnson & Johnson to $160 from $166 and keeps a Neutral rating on the shares. The firm’s revised target, based on a sum-of-the ...

J&J submitted a New Drug Application with the agency for TAR-200 for the treatment of patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC) ...

At ESMO 2024, Bayer will present key results from the Phase III ARANOTE trial on NUBEQA® (darolutamide) for metastatic hormone-sensitive prostate cancer and the PEACE-III study of XOFIGO® (radium-223) ...

Treatment Options for Bladder Cancer: Bringing Life to Years of Sparse Options - Guru Sonpavde ...

Raritan: Johnson & Johnson has announced it has initiated the submission of an original New Drug Application with the U.S. Food and Drug Administration (FDA) for TAR-200 for the treatment of patients ...

Johnson & Johnson JNJ has initiated a rolling submission with the FDA seeking approval for TAR-200, its investigational drug-device combination to treat certain patients with non-muscle invasive ...

Johnson & Johnson (NYSE: JNJ) has started the submission of an original New Drug Application with the US Food and Drug Administration (FDA) for TAR-200. The filing seeks approval for the treatment of ...

Johnson & Johnson initiated an application seeking Food and Drug Administration approval of its TAR-200 drug-device combination for the treatment of certain patients with bladder cancer.

RARITAN, N.J. - Johnson & Johnson (NYSE:JNJ) has begun the process for U.S. Food and Drug Administration (FDA) approval of TAR-200, a new treatment option for high-risk non-muscle-invasive bladder ...

Johnson & Johnson has initiated an application seeking Food and Drug Administration approval of its TAR-200 drug-device combination for the treatment of certain patients with bladder cancer.